SCHEMBL5456323

SCHEMBL5456323

NC(=O)c1c(NC(=O)C2CC2)sc2c1CC/C(=N\OCc1ccccc1)C2

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.51
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.42
TNIK Q9UKE5 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
REV1 Q9UBZ9 1/20 0.40
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456329 1.00 FLT3 (0.51) FLT3MAPTKDM4ETNIKMEN1
SCHEMBL5451573 0.81 FLT3 (0.60) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5451568 0.81 FLT3 (0.60) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5450824 0.81 FLT3 (0.65) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5450827 0.81 FLT3 (0.65) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5457811 0.80 FLT3 (0.49) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5457806 0.80 FLT3 (0.49) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5457803 0.80 FLT3 (0.49) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5467190 0.79 FLT3 (0.65) FLT3MAPTKDM4EMEN1KMT2A
SCHEMBL5467186 0.79 FLT3 (0.65) FLT3MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPT 21/4885KDM4E 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.